myTomorrows, a global health technology company that connects patients with approved treatment options, has announced it has referred 611 patients with Duchenne muscular dystrophy (DMD) around the world to clinical trials and expanded access programs through its AI-powered matching platform. Nearly 300 of these patients have been successfully enrolled, demonstrating how artificial intelligence and personalized care can help people with rare diseases get better access to treatments.
Duchenne muscular dystrophy is a rare genetic condition that causes muscle weakness and loss over time, mainly affecting boys. Symptoms usually start appearing between the ages of two and three. While clinical research is critical for finding better treatments, only about one-third of Duchenne patients in the U.S. have ever taken part in trials. Access to these trials is a big problem. A recent survey by myTomorrows found that more than half of healthcare professionals said the trial referral process was slow and inefficient, and nearly three-quarters said searching for trials was too time-consuming. These challenges are even greater for Duchenne, where trials are limited and quick access is essential.
Health Technology Insights: LPOXY Raises $28 Million Series A to Fund STOP-Cdiff Trial
myTomorrows’ platform uses AI to match patients with clinical trials with up to 98% accuracy. This technology helps reduce the work for research sites and sponsors by automatically comparing patient details with trial requirements. It pulls information from global public trial databases to find relevant studies, helping patients and their doctors get through the logistical difficulties and access new treatments faster. In addition to AI, myTomorrows works with a team of Patient Navigators who offer personal, compassionate support. In 2024, these navigators made over 5,000 multilingual calls to guide patients and families through the process of finding and getting treatment. Their support reaches across the Americas, Europe, Asia Pacific, Africa, and the Middle East. The company also collaborates with patient advocacy groups at major conferences focused on neuromuscular and neurodegenerative diseases to raise awareness and educate about clinical trials and unmet medical needs.
With deep knowledge of neuromuscular disorders, myTomorrows manages over 20 clinical trial recruitment and expanded access programs in partnership with biopharma companies. This shows its commitment to advancing treatments for rare diseases. It also helps patients with conditions like ALS, Parkinson’s disease, and Multiple System Atrophy. Working with organizations such as the ALS Association helps expand access and speed up progress for these patient groups. Terri Ellsworth, a Duchenne advocate and consultant with myTomorrows, shared her personal experiences. She talked about the challenges families face in dealing with the disease and finding treatments. Ellsworth credited participation in clinical trials for the progress her son has made, noting that his involvement in a five-year study helped lead to the first FDA-approved Duchenne drug and set the stage for future therapies. She stressed the importance of awareness days to share stories and build stronger support for families with Duchenne.
Michel van Harten, MD, CEO of myTomorrows, expressed pride in the company’s support for rare disease communities like Duchenne. He highlighted the achievement of referring and enrolling hundreds of patients into clinical trials and expanded access programs as an important step forward. Van Harten said each patient represents a family going through a tough journey, and myTomorrows is honored to help them. He also mentioned the company’s ongoing commitment to growing its reach and improving support as its technology develops to better serve the Duchenne community. myTomorrows runs a secure and compliant platform that meets standards like ISO 27001, GDPR, SOC 2, and HIPAA. It also connects with electronic health records to provide accurate and useful matches for patients and healthcare providers.
Health Technology Insights: Elsevier Unveils PharmaPendium AI for Drug Development
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
